Skip to main content

Table 6 Intensities of the peaks for different categories of hormone-receptor status, Her2/neu and P53 expression and menopause status

From: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study

  

M/z4276

M/z4292

M/z8129

M/z8941

 

n

Median intensity

(IQR)

Median intensity

(IQR)

Median intensity

(IQR)

Median intensity

(IQR)

ER status

     

   Negative

12

15.2

(0.7–70.6)

18.3

(6.2–48.1)

26.3

(25.2–28.5)

39.9

(24.3–57.5)

   Positive

35

11.0

(3.9–24.3)

14.5

(8.9–22.9)

25.7

(17.9–28.2)

30.5

(24.1–43.4)

p-value*

47

.961

.696

.421

.380

PR status

     

   Negative

19

7.1

(4.0–29.3)

10.9

(8.5–30.8)

26.0

(21.7–27.8)

31.3

(24.0–43.3)

   Positive

28

14.6

(1.8–28.2)

15.4

(6.8–28.7)

25.8

(19.5–29.6)

32.1

(24.1–46.7)

p-value*

47

.649

.696

.762

.588

Her2/neu expression

     

   Negative

35

11.0

(1.9–29.3)

15.9

(5.6–29.5)

25.9

(20.5–27.8)

32.9

(24.1–46.9)

   Positive

12

9.5

(4.3–66.2)

11.1

(9.1–43.2)

26.0

(16.2–29.3)

29.7

(23.3–41.7)

p-value*

47

.961

.826

.751

.575

P53 expression

     

   Negative

18

6.5

(1.6–24.3)

12.7

(5.3–31.3)

23.7

(17.6–26.8)

27.1

(17.7–42.6)

   Positive

23

11.0

(4.7–29.4)

14.9

(8.9–29.5)

26.5

(24.8–30.1)

32.9

(27.8–60.8)

p-value*

41

.599

.546

.070

.172

Menopause status

     

   Premenopausal

15

7.9

(1.9– 84.3)

12.2

(10.1–69.2)

27.6

(22.2–32.7)

29.0

(22.7–43.3)

   Postmenopausal

30

10.2

(2.0–25.6)

14.3

(5.5–29.8)

25.3

(17.8–26.6)

32.1

(24.2–45.4)

p-value*

45

.942

.580

.030

.563

  1. M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Mann-Whitney U Test, ER = Oestrogen Receptor, PR = Progesterone Receptor